Ingenol Mebutate Gel for Actinic Keratosis

Abstract

Ingenol mebutate gel applied topically for 2 to 3 days is effective for field treatment of actinic keratoses. (Funded by LEO Pharma; ClinicalTrials.gov numbers, NCT00742391, NCT00916006, NCT00915551, and NCT00942604.).

Topical agents for preventing and treating actinic keratosis

“…18 In a separate study in 203 patients with AK on the face or scalp with lesions persisting eight weeks after treatment with ingenol mebutate, or in whom lesions emerged after 26 or 44 weeks, the complete clearance rate after a second treatment cycle was significantly greater than with vehicle (47 vs 18 per cent), with an overall clearance rate at 12 months of 50 per cent. 19 Ingenol mebutate causes erythema, flaking, scaling and crusting within one day; this reaches maximum intensity during the first week after treatment, but usually resolves within two weeks for the face and scalp and four weeks for the trunk and extremities (see Figure 1).…”

“…18 These studies were double-blinded, but it is possible that blinding was compromised by the marked skin reaction associated with treatment. At eight weeks after ending treatment, the complete clearance rate for AK on the face and scalp was significantly greater for ingenol mebutate (42 vs 3.7 per cent with vehicle), with partial clearance in 64 and 7.4 per cent of patients respectively.…”

“…19 Ingenol mebutate causes erythema, flaking, scaling and crusting within one day; this reaches maximum intensity during the first week after treatment, but usually resolves within two weeks for the face and scalp and four weeks for the trunk and extremities (see Figure 1). 18 Treatment is assessed after eight weeks.…”

Protein kinase C-dependent regulation of human hepatic drug transporter expression

“…To determine whether drug transporters regulated by PMA in HepaRG cells may also be targeted by the phorbol ester in human hepatocytes, primary human hepatocytes were To investigate whether PKC activating agents distinct from PMA may also regulate transporter mRNA expression in HepaRG cells, we finally exposed these highly-differentiated human hepatoma cells to 10 µM ingenol mebutate (also known as PEP005), a small molecule activator of PKCs, used for the topical treatment of actinic keratosis [33] and also exhibiting anticancerous activity [34]. As shown in Fig.…”

Severe local skin reaction after the application of ingenol mebutate gel treated by photodynamic therapy: A case report

“…It consists of self-administered therapy by applying IM on the affected skin surface with multiple AK for two consecutive days (trunk and extremities) or three days (scalp and face). It is considered a safe and effective treatment in spite of local reactions frequently reported [1] . These reactions may consist of erythema, flaking, crusting, swelling, vesicles and erosions, and would usually spontaneously recede within 20-30 days [2] .…”